StreetInsider.com News Articles

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Wed, 10 Jun 2026 02:35:00 -0400

OpenFold’s mission is provide researchers from academia and industry with access to

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026

Tue, 26 May 2026 06:22:00 -0400

Tokyo, Japan and Cambridge, UK, 26 May 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference on Wednesday,3rd June at 3:45 p.m. EDT / 4th 4:45 a.m. JST. During the event, Mr. Cargill will present the Company’s strategy, recent progress and expected upcoming milestones to leading global life sciences investors.

The live webcast of the ‘Fireside Chat’ will be available here.

The replay will also be available at

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026

Tue, 26 May 2026 06:22:00 -0400

The live webcast of the ‘Fireside Chat’ will be available here.

The replay will also be available at

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026

Tue, 26 May 2026 06:22:00 -0400

The live webcast of the ‘Fireside Chat’ will be available here.

The replay will also be available at

Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies New York Healthcare Conference 2026

Tue, 26 May 2026 06:22:00 -0400

The live webcast of the ‘Fireside Chat’ will be available here.

The replay will also be available at

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Mon, 11 May 2026 02:34:00 -0400

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.
In return for granting an exclusive worldwide license to the program, Nxera is eligible to receive up to US$275 million in development and commercial milestone payments as well as tiered royalties. In addition, Nxera retains rights to Japan and certain Asia-Pacific territories and now holds a significant minority equity stake in the NewCo.
Builds toward the establishment of an asset spin-out model, following Orexia Therapeutics/Centessa Pharmaceuticals, which announced an agreement to be acquired by Lilly.

Tokyo, Japan

Nxera Pharma files patent suit against OMass over miniG technology

Fri, 08 May 2026 06:26:41 -0400

Nxera Pharma Co., Ltd. (TSE: 4565) announced that its subsidiary Nxera Pharma UK Limited has filed patent infringement proceedings against OMass Therapeutics in the Patents Court of the High Court of Justice of England and Wales.

The lawsuit alleges infringement of patents EP 3 408 286 B1 and GB 2 558 968 B, which relate to Nxera's miniG technology. The miniG technology is part of the company's NxWave GPCR-focused structure-based drug discovery platform.

Nxera is seeking compensation and injunctive relief to prevent further infringement, according to the company's statement. The company said it does not intend to comment further while the matter